|
Urology News and Education Resource
 |
Friday, 01 November 2024 |
|
 |
|
Every month UroToday will feature a full text article and commentary from the journal: Prostate Cancer and Prostatic Diseases (PCAN). Each commentary is original content written by PCAN’s editor-in-chief, Stephen Freedland, MD and will also feature associate editor, Andrew Armstrong, MD. Here you will find 3 full text articles and corresponding commentaries.
|
|
|
Full text article: Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastases—analysis of an international multicenter database
Radium-223 is an alpha-emitting radioisotope with calcium-mimetic properties, which therefore accumulates in bone areas with an increased turnover. Radium-223 targets bone metastases, and improves overall survival in patients with bone metastases, but is not indicated in mCRPC patients with visceral or bulky lymph node disease. Improved overall survival was observed in the pivotal phase 3 ALSYMPCA trial.
|
|
|
From the Desk of the Associate Editor: Radium-223 Radiographic Response
Keizman and colleagues recently reported on their large multicenter experience with radium-223 following regulatory approval for men with metastatic prostate cancer. In their study, which was conducted across Switzerland, Denmark, and Israel, patients were treated similarly to ALSYMPCA but many men received concurrent enzalutamide or abiraterone acetate, which were not available during the ALSYMPCA trial.
|
|
|
|
Full text article: Which, when and why? Rational use of tissue-based molecular testing in localized prostate cancer
Localized prostate cancer represents a disease spectrum, with ideal treatment varying from watchful waiting to immediate multi-modal therapy. Although clinical and pathological features of disease can guide decision making, there remains ambiguity even among risk-stratified patients. An increased molecular understanding of localized prostate cancer and facility for molecular testing has led to the development of tissue-based assays that may help decrease the uncertainty in decision making.
|
|
|
From the Desk of the Editor: Testing in Localized Prostate Cancer
Into this morass of risk stratification, steps molecular markers. There are now many markers available – either using tissue, blood, or urine. Given that a comprehensive review of all markers for all applications would be beyond a single review, Ross et al, focused on tissue-based molecular markers
|
|
|
|
Full text article: Increasing incidence of metastatic prostate cancer in the
United States (2004–2013).
Over the past decade, there has been substantial shifts in PSA screening practices in response to randomized trial data and US Preventive Services Task Force (USPSTF) recommendations in 2008 and 2012.This has resulted in reduced screening with associated declines in overall prostate cancer incidence. Using data from a large cancer registry from 2004 through 2013, we sought to analyze the temporal relationship between relaxed screening and increases in yearly incidence of advanced or metastatic prostate cancer
|
|
|
From the Desk of the Editor: Increasing incidence of metastatic prostate cancer in the United States
This controversy has led to backlash against PSA screening, most notably the US Preventative Task Force recommending against PSA screening in 2012. Under this backdrop, rates of PSA screening in the US have been declining for several years, predating the change from the USPTF.
|
|
|
|
|
|
|
You are receiving this email because you have chosen to receive emails from UroToday...
Subscribe | Unsubscribe
|
View on Web
Forward
Follow UroToday
 
Digital Science Press,Inc.
11448 Deerfield Drive, Suite 2
Truckee, CA, 96161 USA
|
|
